Core Insights - Palm Valley Capital Fund reported a 0.66% appreciation in Q4 2025, underperforming the S&P SmallCap 600's 1.70% gain and the Morningstar Small Cap Total Return Index's 3.12% rise [1] - The Fund increased its allocation to Treasury bills from 74.1% to 76.3% during the quarter, while equity holdings rose by 1.12% [1] - Investments in precious metals, particularly silver, positively influenced equity performance, which has been a significant allocation for the Fund in recent years [1] Company Highlights - Ingredion Incorporated (NYSE:INGR) was highlighted as a key stock in the Fund's Q4 2025 investor letter, with a one-month return of 3.89% and a 52-week loss of 16.81% [2] - As of January 5, 2026, Ingredion's stock closed at $110.41 per share, with a market capitalization of $7.086 billion [2] - The Fund initiated new positions in Ingredion, along with Domino's Pizza Group plc and Utz Brands, with modest initial weightings due to reaching minimum required discounts [3]

Core Insights - Rep. Marjorie Taylor Greene and Bill Gates share five common stocks in their investment portfolios, indicating potential investment strategies and interests [1][2]. Group 1: Shared Stocks - Berkshire Hathaway Inc (NYSE:BRK) is the top holding in the Gates Foundation Trust, with 21,765,224 shares owned at the end of Q3, constituting approximately 30% of the trust's assets [3]. - Microsoft Corp (NASDAQ:MSFT) is now the fourth-largest holding in the Gates Foundation Trust, with 9,191,207 shares valued at $4.8 billion, representing around 13% of the trust [4]. - Caterpillar Inc (NYSE:CAT) is the fifth-largest holding in the Gates Foundation Trust, with 6,353,614 shares worth an estimated $3 billion, accounting for about 8.3% of the trust's assets [5]. - Walmart Inc (NASDAQ:WMT) is the eighth-largest holding in the Gates Foundation Trust, representing around 2.4% of assets, with 8,390,477 shares owned at the end of Q3 [7].

Core Viewpoint - Pfizer's shares are currently trading at approximately $25, reflecting a challenging performance over the past three years, raising questions about the company's investment potential moving forward [1] Group 1: Financial Performance - Pfizer's revenue and earnings have shown inconsistency in recent years, compounded by upcoming patent cliffs, notably for Eliquis, one of its top-selling drugs [3] - The company has been gradually securing new approvals that could positively impact its financial results through label expansions [3] Group 2: Strategic Moves - Pfizer has intensified its acquisition strategy, enhancing its product pipeline with a focus on cancer therapies and a promising weight loss candidate [4] - The company is expected to launch several new products that will strengthen its portfolio through the end of the decade [4] Group 3: Investment Considerations - Pfizer has established a deal with the Trump administration to avoid tariffs for three years, which could benefit its financial standing [8] - The company has a strong dividend history, increasing payouts by 51.3% over the past decade, with a current yield of 6.9% [8] - Pfizer's stock is trading at 8.5 times forward earnings, significantly lower than the healthcare sector average of 18.4, making it an attractive investment option [8]

Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The Wall Street Journal Barron's MarketWatch Dow Jones Smart Money Connect With Us On stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any speci ...

Core Insights - Encompass Health Corporation (EHC) is experiencing growth due to increasing patient volumes, expansion initiatives, and a strong financial position [1] Financial Performance - EHC has a Zacks Rank of 2 (Buy) and its stock has increased by 16.6% over the past year, outperforming the industry growth of 7.2% [2] - The Zacks Consensus Estimate for EHC's 2025 earnings is $5.30 per share, reflecting a year-over-year increase of 19.6%, with revenues expected to reach $5.9 billion, indicating a 10.4% growth [5] - The 2026 earnings estimate is $5.81 per share, showing a 9.6% increase from 2025 [5] - The consensus estimate for 2026 revenues is projected at $6.5 billion, representing an 8.8% growth from the 2025 estimate [6] - EHC's earnings have consistently surpassed estimates, with an average surprise of 12.47% over the last four quarters [8] Growth Drivers - EHC's revenue growth is primarily driven by an expanding patient base in its inpatient rehabilitation hospitals, with a reported 10.6% revenue increase in the first nine months of 2025 compared to the same period in the previous year [9] - The company plans to add 150-200 beds in both 2026 and 2027, supported by a robust financial foundation, including $48.7 million in cash and cash equivalents as of September 30, 2025, and $829.6 million in operating cash flows for the first nine months of 2025, a 14.6% year-over-year increase [12] Expansion Initiatives - EHC is actively launching new inpatient rehabilitation hospitals, either independently or in collaboration with healthcare partners, enhancing its service capacity and nationwide footprint [10] - As of now, EHC operates 173 hospitals across 39 states and Puerto Rico, with the latest addition being the Rehabilitation Hospital of Lake Worth, opened in December [11]

Core Viewpoint - Boeing had a strong performance in 2025, and hedge fund manager Dan Niles anticipates continued stock growth into 2026, labeling it a "top pick" for the year in a CNBC interview [1] Group 1 - Boeing's stock is expected to keep climbing, driven by positive market sentiment and strong financial results [1] - Dan Niles' endorsement highlights investor confidence in Boeing's future prospects [1]

Core Insights - Coupang has acquired the luxury fashion marketplace Farfetch to enter the high-end retail segment and is focusing on building a luxury presence in Asia while facing challenges in sales growth and the luxury e-commerce landscape [1] - The company operates a subscription service called Rocket WOW, which offers benefits like free express delivery and access to various services, including food delivery and video streaming [2] - Coupang's logistics model allows over 70% of South Koreans to receive same-day or next-morning delivery, enhancing its competitive edge in the e-commerce market [3][4] Financial Performance - In the third quarter, Coupang reported net revenues of $9.3 billion, an 18% year-over-year increase, and net income of $95 million, up 48% from the previous year [7] - Following a data breach affecting over 33 million customers, the stock has experienced volatility, but analysts believe the business remains robust and could see significant stock price increases in the next 12 months [8] Market Position - Coupang is recognized as the dominant e-commerce platform in South Korea, often referred to as the "Amazon of South Korea," due to its vertically integrated logistics network [4] - The company has a growing advertising revenue stream, allowing sellers to promote products within the Coupang app [6]

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. ©2025 Investor's Business Daily, LLC. All Rights Reserved. About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Check ...

Core Insights - Elon Musk's purchase of Tesla shares in September 2025 has resulted in significant paper gains as the stock price increased towards the end of the year [1] - The shares were acquired at an average price of approximately $395.94, totaling around $1 billion, marking one of Musk's largest personal investments in Tesla [1] - As of December 28, 2025, Tesla shares were trading at approximately $475.19, reflecting a 20% increase from the purchase price, with Musk's stake now valued at about $1.2 billion [2] Stock Performance Overview - Tesla shares experienced volatility in 2025, initially declining due to Musk's focus on government work and weakening global sales, but rebounded strongly in December [3][4] - The stock's recovery was significant, pushing returns on Musk's investment well above the interim lows experienced earlier in the year [3] Market Sentiment and Investor Confidence - Investor sentiment improved in April 2025 when Musk announced a reduction in his Washington role, alleviating concerns about leadership focus and leading to a rally in Tesla's stock [4] - Momentum strengthened in May following a tariff truce between the US and China, which positively impacted Tesla's supply chain and international demand [6] - Tesla's board proposed a substantial compensation package for Musk, further boosting investor confidence, coinciding with Musk's $1 billion stock purchase, signaling strong belief in the company's future [6]